# Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery

> **NCT00305877** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 137 (actual)

## Conditions studied

- Stage IA Pancreatic Cancer
- Stage IB Pancreatic Cancer
- Stage IIA Pancreatic Cancer
- Stage IIB Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** capecitabine
- **RADIATION:** radiation therapy
- **BIOLOGICAL:** bevacizumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00305877
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-07
- **Final completion:** 2012-02
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305877, "Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00305877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*